There’s been a huge increase in conversations around GLP-1 medications over the past couple of years, particularly in relation to weight management. However, a lot of what’s shared online tends to oversimplify things, and often misses the bigger clinical picture. These medications weren’t originally developed for weight loss, and their role in the body is much more complex than simply reducing appetite.
To understand how they work, it helps to go back to the basics of physiology. GLP-1, or glucagon-like peptide-1, is a hormone that your body naturally produces in the gut in response to food intake. It forms part of what’s known as the incretin system, which plays a key role in regulating blood glucose levels after eating. When GLP-1 is released, it stimulates insulin secretion from the pancreas in a glucose-dependent way – meaning it works when blood sugar levels are elevated rather than continuously. At the same time, it suppresses glucagon release, which reduces the amount of glucose produced by the liver.
Alongside these effects on blood sugar, GLP-1 also influences gastric emptying, slowing down how quickly food leaves the stomach. This contributes to a more gradual rise in blood glucose and can also affect satiety, or how full we feel after eating. In addition, GLP-1 receptors are present in areas of the brain involved in appetite regulation, which is why these medications can influence hunger and food intake. Taken together, these mechanisms explain why GLP-1 receptor agonists have been used for many years in the management of type 2 diabetes, before their effects on weight were more widely recognised.
More recently, research has expanded into medications that act on both GLP-1 and another incretin hormone called GIP, or glucose-dependent insulinotropic polypeptide. GIP is also released after food intake and plays a role in insulin secretion, but it appears to have additional effects on energy balance, fat metabolism, and possibly how the body stores and uses nutrients. The rationale behind dual-acting medications is that by targeting both GLP-1 and GIP pathways, we may be able to influence multiple aspects of metabolic regulation simultaneously, rather than focusing on a single mechanism.
This is where much of the newer research sits. Large-scale clinical trials have looked at how these medications perform in different populations, particularly in individuals living with overweight or obesity, often alongside lifestyle interventions. The STEP trial programme, for example, investigated GLP-1 receptor agonists in people without diabetes but with increased body weight. Across these studies, participants receiving the medication alongside lifestyle support experienced greater average reductions in body weight compared to those receiving lifestyle intervention alone. There were also improvements seen in markers such as waist circumference, blood pressure, and glycaemic control.
Similarly, the SURMOUNT trial programme explored dual GLP-1/GIP receptor agonists. These studies reported further average reductions in body weight in certain groups, as well as improvements in metabolic markers. However, it’s important to interpret these findings carefully. Clinical trial results are based on group averages under controlled conditions, and they don’t always translate directly to individual outcomes in real-world settings. Factors such as baseline health, adherence to treatment, lifestyle habits, and underlying metabolic conditions all influence how someone responds.
Another important point that often gets overlooked is that in these trials, participants were not relying on medication alone. Structured lifestyle support — including dietary guidance, behavioural changes, and physical activity — formed a core part of the intervention. This reinforces the idea that these medications are designed to support metabolic processes rather than replace the fundamentals of lifestyle management.
From a clinical and regulatory perspective, it’s also essential to understand that these treatments are prescription-only medicines. This means they require an appropriate face to face medical assessment before they can be considered, including a review of medical history, potential contraindications, and individual risk factors. Ongoing monitoring is also important to ensure safety and to assess how someone is responding over time.
Like all medications, GLP-1 and GIP therapies are associated with potential side effects. The most commonly reported are gastrointestinal, including nausea, vomiting, diarrhoea, or reduced appetite, particularly during the initial stages of treatment or when doses are increased. These effects are usually related to how the medication interacts with the gut and central appetite pathways. For this reason, treatment is typically introduced gradually, with careful dose escalation to improve tolerability.
There are also broader considerations around suitability. These medications are not appropriate for everyone, and their use needs to be individualised. Clinical guidelines highlight the importance of assessing both physical and psychological factors, as well as ensuring that patients have realistic expectations about what treatment can and cannot achieve. While some individuals experience significant changes, others may see more modest effects, and this variability is an important part of informed decision-making.
What’s often missing from online discussions is that these medications are part of a wider conversation about metabolic health, rather than just weight. They interact with systems that regulate blood glucose, appetite, energy balance, and potentially cardiovascular risk. This is why their use sits within a broader clinical framework, rather than being viewed as a standalone solution.
As research continues, we’re likely to see further developments in this area, with ongoing studies exploring long-term outcomes, different patient groups, and additional metabolic effects. However, as with any emerging area of medicine, it’s important to approach the topic with a balanced, evidence-based perspective. These treatments can play a role in certain clinical contexts, but they are not a universal solution, and their use should always be guided by appropriate medical advice.
Revive Aesthetics Bridgend 2025 